* Arigene says unable to secure sufficient financing
* Trimeris gets $12 mln as termination fee
* Trimeris shares down 13 pct
Dec 29 - Arigene Co Ltd (067850.KQ), a South Korean medical equipment maker, said it terminated its tender offer for the outstanding common stock of Trimeris Inc (TRMS.O) as the company was unable to secure sufficient fund for the deal.
On Oct. 2, Arigene agreed to acquire biopharmaceutical company Trimeris for $81 million through a cash tender offer of $3.60 per share.
Separately, Trimeris said after amending the merger agreement on Nov. 17, which extended the tender offer to Dec. 28, it received $12 million as reverse termination fee.
Trimeris shares were down 13 percent at $2.75 Tuesday on Nasdaq.
For the alerts double-click [ID:nWNBB4462] [ID:nWNBB4492]. (Reporting by Anand Basu in Bangalore; Editing by Maju Samuel)